Aeterna Zentaris Inc. (AEZS) |
|
3.73 0.05 (1.36%)
|
01-27 15:59 |
|
Open: |
3.74 |
Pre. Close: |
3.68 |
|
High:
|
3.8 |
Low:
|
3.66 |
|
Volume:
|
9,774 |
Market Cap:
|
18(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:42:19 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 4.59 One year: 5.36 |
| Support: |
Support1: 3.28 Support2: 2.89 |
| Resistance: |
Resistance1: 3.93 Resistance2: 4.59 |
| Pivot: |
3.72  |
| Moving Average: |
MA(5): 3.74  MA(20): 3.6
MA(100): 3.8 MA(250): 5.43 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 68.5 %D(3): 73.4 |
| RSI: |
RSI(14): 55.9 |
| 52-week: |
High: 11 Low: 0.16 |
| Average Vol(K): |
3-Month: 15 (K) 10-Days: 16 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ AEZS ] has closed below upper band by 48.4%. Bollinger Bands are 51.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.8 - 3.83 |
3.83 - 3.85 |
|
Low:
|
3.61 - 3.64 |
3.64 - 3.66 |
|
Close:
|
3.69 - 3.74 |
3.74 - 3.77 |
|
Company Description |
|
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina. |
Headline News |
Tue, 17 Jan 2023
Aeterna Zentaris Provides Business Update and Outlines Key ... - GlobeNewswire
Tue, 10 Jan 2023
Aeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch Event - Financial Post
Thu, 03 Nov 2022
Aeterna Zentaris Reports Third Quarter 2022 Financial Results - GlobeNewswire
Mon, 29 Aug 2022
Aeterna Zentaris Set to Regain Full Rights to Macrilen ... - GlobeNewswire
Mon, 18 Jul 2022
Aeterna Zentaris Announces Effective Date of Share Consolidation - GlobeNewswire
Tue, 21 Jun 2022
Aeterna Zentaris Announces Results of Annual Meeting of ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
5 (M) |
| Shares Float |
5 (M) |
|
% Held by Insiders
|
0.3 (%) |
|
% Held by Institutions
|
0.6 (%) |
|
Shares Short
|
95 (K) |
|
Shares Short P.Month
|
100 (K) |
Stock Financials |
|
EPS
|
-0.08 |
|
EPS Est Next Qtl
|
-0.26 |
|
EPS Est This Year
|
-1.02 |
|
EPS Est Next Year
|
-0.29 |
|
Book Value (p.s.)
|
10.18 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-349.9 |
|
Return on Assets (ttm)
|
-12.1 |
|
Return on Equity (ttm)
|
-24.1 |
|
Qtrly Rev. Growth
|
76.8 |
|
Gross Profit (p.s.)
|
1.06 |
|
Sales Per Share
|
0.84 |
|
EBITDA (p.s.)
|
-2.96 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-13 (M) |
|
Levered Free Cash Flow
|
-8 (M) |
Stock Valuations |
|
PE Ratio
|
-47.22 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.36 |
|
Price to Sales
|
4.41 |
|
Price to Cash Flow
|
-1.44 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
